Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Varsha Gandhi, PhD, on Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

May

Today In Oncology

Addition of Durvalumab to Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer PROs in TOPAZ-1

Omission of Axillary Dissection After Nodal Downstaging With Neoadjuvant Chemotherapy in Breast Cancer

Local Recurrence of Endometrial Cancer Radiotherapy With or Without Cisplatin

Historical Community Outreach and Engagement Efforts at NCI-Designated Cancer Centers

Newly Identified Biomarkers May Improve Diagnosis and Treatment of RCC Subtypes